Skip to main content
SpringerLink
Log in

Oesophageal Candidiasis in Elderly Patients

Risk Factors, Prevention and Management

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

This article reviews risk factors, prevention and management of oesophageal candidiasis (OC) in the elderly. Putative risk factors for OC in the elderly include old age itself, malignant disease, antibacterial and corticosteroid use, chronic obstructive pulmonary disease, acid suppression treatment, oesophageal dysmotility and other local factors, diabetes mellitus and HIV/AIDS. We have found evidence for a risk association between OC in the elderly and malignant disease (both haematological and non-haematological), antibacterial therapy and corticosteroid (including inhaled corticosteroids) use. We also found evidence of an association between OC in the elderly and oesophageal dysmotility or HIV/AIDS, but little direct evidence of an association between diabetes or old age per se. The literature on OC in the elderly is not large. The published series evaluating OC in this age group are small in size, often do not contain controls and mostly contain only limited information about the age of the patients. Prevention of OC is mainly the avoidance of exposure to the risk factors wherever possible. Specific measures such as highly active antiretroviral therapy in AIDS, prophylactic fluconazole when receiving chemotherapy for malignancy, using spacing devices, mouth rinsing soon after inhalation of corticosteroids and avoiding the use of cortiocosteroids just before bedtime are useful. OC is often responsive to a 2- to 3-week course of oral fluconazole, but resistance may be encountered in AIDS or in the presence of uncorrected anatomical factors in the oesophagus. Itraconazole solution, voriconazole or caspofungin may be used in refractory cases. Use of amphotericin B is restricted because of its narrow therapeutic index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Laine L, Boncini M. Esophageal disease in human immunodeficiency virus infections. Arch Intern Med 1994; 154: 1577–82

    Article  CAS  PubMed  Google Scholar 

  2. Wilcox CM, Karowe MW. Esophageal infections: aetiology, diagnosis and management. Gastroenterology 1994; 2: 188–206

    CAS  Google Scholar 

  3. Roseff SA, Sugar AM. Oral and esophageal candidiasis in candidiasis: pathogenesis, diagnosis and treatment. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis and treatment. New York: Raven Press Ltd, 1993: 185–203

    Google Scholar 

  4. Adams F, translator. Hippocrates C460-377BC. Epidemics, book 3. Baltimore (MD): Williams & Wilkins, 1939: 23

    Google Scholar 

  5. Trousseau A. Lectures on clinical medicine. Vol. 2. Delivered at the Hotel-Dieu, Paris 1868 [translated by Cormack JR]. London: New Sydenham Society, 1869

    Google Scholar 

  6. Maibach HI, Kligman AM. The biology of experimental human cutaneous moniliasis. Arch Dermatol 1962; 85: 233–55

    Article  CAS  PubMed  Google Scholar 

  7. Phaosawasdi K, Rice P, Lee B, et al. Primary and secondary Candida esophagitis. Illinois Med J 1986; 169: 361–5

    CAS  Google Scholar 

  8. Gentles JC, La Touche CJ. Yeasts as human and animal pathogens. In: Rose AH, Harrison JS, editors. The yeasts. Vol 1. London: Academic Press, 1969: 108–82

    Google Scholar 

  9. Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988: 94–116

    Google Scholar 

  10. Weerasuriya N, Snape J. A study of Candida oesophagitis in elderly patients attending a district general hospital in the UK. Dis Esophagus 2006; 19: 189–92

    Article  CAS  PubMed  Google Scholar 

  11. Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza A, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis 2000; 19: 96–100

    Article  CAS  PubMed  Google Scholar 

  12. Naito Y, Yoshikawa T, Oyamada H, et al. Esophageal candidiasis. Gastroenterology Jpn 1988; 23: 363–70

    CAS  Google Scholar 

  13. Bhatia V, Kochlar R, Talwar P, et al. Association of Candida with cancer of the esophagus. Indian J Gastroenterol 1989; 8: 171–2

    CAS  PubMed  Google Scholar 

  14. Harvey CF, Mills JO, Barros AA. Oesophageal moniliasis. Br J Clin Pract 1986; 40(1): 36–40

    CAS  PubMed  Google Scholar 

  15. Yakoob J, Jafri W, Abid S, et al. Candidal esophagitis: risk factors in non HIV population in Pakistan. World J Gastroenterol 2003; 9: 2328–31

    PubMed  Google Scholar 

  16. Baskol M, Ozbakir O, Gursoy S, et al. Candida esophagitis. Turk J Gastroenterol 2001; 12: 19–22

    Google Scholar 

  17. Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut 1982; 23: 137–9

    Article  CAS  PubMed  Google Scholar 

  18. Bjorn Jensen K, Stenderup A, Brown Thomsen J, et al. Oesophageal moniliasis in malignant neoplastic disease. Acta Medica Scand 1964; 175: 455–9

    Article  Google Scholar 

  19. Holt JM. Candida infection in the oesophagus. Gut 1968; 9: 227–31

    Article  CAS  PubMed  Google Scholar 

  20. Gundry SR, Borkon AM, McIntosh CL, et al. Candida oesophagitis following a cardiac operation and short term antibiotic prophylaxis. J Thorac Cardiovasc Surg 1980; 80: 661–8

    CAS  PubMed  Google Scholar 

  21. Kesten S, Hyland RH, Pruzanski WR, et al. Candida oesophagitis associated with beclomethasone dipropionate aerosol therapy. Drug Intell Clin Pharm 1988; 22: 568–9

    CAS  PubMed  Google Scholar 

  22. Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with fluticasone propionate. Am J Gastroenterol 2003; 98: 2146–8

    Article  CAS  PubMed  Google Scholar 

  23. Chung CH. Oesophageal candidiasis after prolonged use of inhaled corticosteroids. Hong Kong Pract 2002; 24: 248–52

    Google Scholar 

  24. Simon MR, Houser WL, Smith KA, et al. Esophageal Candida as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol 1997; 79: 333–8

    Article  CAS  PubMed  Google Scholar 

  25. Larner AJ, Lendrum R. Oesophageal candidiasis after omeprazole therapy. Gut 1992; 33: 860–1

    Article  CAS  PubMed  Google Scholar 

  26. Mossiman F. Esophageal candidiasis, omeprazole treatment and organ transplantation. Transplantation 1993; 56: 492–3

    Article  Google Scholar 

  27. Good A, Sharma M, Jain NP, et al. Esophageal candidiasis following omeprazole treatment: 2 cases. Indian J Gastroenterol 1995; 14: 71–2

    Google Scholar 

  28. Gefter WB, Laufer I, Edell S, et al. Candidiasis in obstructed esophagus. Radiology 1981; 138: 25–8

    CAS  PubMed  Google Scholar 

  29. Troupin RH. Intramural diverticulosis and moniliasis. AMJ Roentgenol 1968; 104: 613–6

    CAS  Google Scholar 

  30. Castillo S, Aburashed A, Kimmelman J, et al. Diffuse intra mural esophageal pseudo diverticulosis. Gastroenterol 1972; 72: 541–2

    Google Scholar 

  31. deGorgolas M, Bello E, Garcia-Vazquez E, et al. In old age: AIDS review of 37 patients over 60 years old. Ann Med Intern 1999; 16: 273–6

    CAS  Google Scholar 

  32. Gomez MA, Hunter R, Minino A. HIV/AIDS in a late middle aged and elderly Puerto Rican population [abstract no. 127]. Abstract search tools, National HIV Prevention Conference; 1999 Aug 29–Sep 1; Atlanta (GA)

  33. Parkman HP, Schwartz SS. Esophagitis and gastro duodenal disorders associated with diabetic gastro paresis. Arch Intern Med 1987; 147: 1477–80

    Article  CAS  PubMed  Google Scholar 

  34. Fisher BM, Lamey PJ, Samaranayake LP, et al. Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. J Oral Pathol 1987; 16: 282–4

    Article  CAS  PubMed  Google Scholar 

  35. Kodsi BE, Wickremesinghe PC, Kozinn PJ, et al. Candida oesophagitis, a prospective study of 27 cases. Gastroenterol 1976; 71: 715–9

    CAS  Google Scholar 

  36. Lehrer RI, Cline MJ. Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancer. Cancer 1971; 27: 1211–7

    Article  CAS  PubMed  Google Scholar 

  37. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am 2002; 16: 793–820

    Article  PubMed  Google Scholar 

  38. Walsh TH, Hamilton SR, Belitos N. Esophageal candidiasis: managing our increasingly prevalent condition. Postgrad Med 1988; 84: 193–205

    CAS  PubMed  Google Scholar 

  39. Silverman S, Luangjarmekorn L, Greenspan D. Occurrence of oral Candida in irradiated head and neck cancer patients. J Oral Med 1984; 39: 194–6

    PubMed  Google Scholar 

  40. Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988: 156–60

    Google Scholar 

  41. Seelig MS. The role of antibiotics in the pathogenesis of Candida infection. Am J Med 1966; 40: 887–917

    Article  CAS  PubMed  Google Scholar 

  42. Gencosmanoglur R, Kurtkayer-Yapicier O, Tiftikci A, et al. Mid oesophageal ulceration and Candida associated distal oesophagitis as 2 distinct clinical patterns of tetracycline or doxycycline induced oesophageal injury. J Clin Gastroenterol 2004; 38: 484–9

    Article  Google Scholar 

  43. Dennis H, Itkin IG. Effectiveness and complications of aerosol dexamethasone phosphate in severe asthma. J Allergy 1964; 35: 70–3

    Article  CAS  PubMed  Google Scholar 

  44. Smith MJ, Hodson ME. High dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; I: 265–9

    Article  Google Scholar 

  45. Torak RM. Fungus infections associated with antibiotic and steroid therapy. Am J Med 1957; 22: 872–82

    Article  Google Scholar 

  46. Tapper-Jones LM, Alfred MJ, Walker DM, et al. Candidal infections and populations of C. albicans in the mouths of diabetics. J Clin Pathol 1981; 24: 706–11

    Article  Google Scholar 

  47. Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980; 25: 1–10

    Article  CAS  PubMed  Google Scholar 

  48. Karmeli Y, Stalnikowitz R, Eliakim R, et al. Conventional dose omeprazole alters gastric flora. Dig Dis Sci 1995; 40: 2070–3

    Article  CAS  PubMed  Google Scholar 

  49. Hendel L, Svejgaard E, Walsoe I, et al. Esophageal Candida in progressive systemic sclerosis: occurrence, significance and treatment with fluconazole. Scand J Gastroenterol 1988; 23: 1182–6

    Article  CAS  PubMed  Google Scholar 

  50. Scaringi L, Cornacchione P, Fettucciari K, et al. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 1996; 44: 204–14

    Article  CAS  PubMed  Google Scholar 

  51. Teare JP, Spedding C, Whitehead MW, et al. Omeprazole and dry mouth. Scand J Gastroenterol 1993; 30: 216–8

    Article  Google Scholar 

  52. Knight L, Fletcher J. Growth of C. albicans in saliva: stimulation by glucose, associated with antibiotics, corticosteroids and diabetes mellitus. J Infect Dis 1971; 123: 371–7

    Article  CAS  PubMed  Google Scholar 

  53. Odds FC, Evans EGV, Taylor MAR, et al. Prevalence of pathogenic yeasts and humoral antibodies to Candida in diabetic patients. J Clin Pathol 1987; 31: 840–4

    Article  Google Scholar 

  54. Wilson RM, Reeves WC. Neutrophil phagocytosis and killing in insulin dependent diabetes. Clin Exp Immunol 1986; 63: 478–84

    CAS  PubMed  Google Scholar 

  55. Hill LVH, Tan MH, Pereira LH, et al. Association of oral candidiasis with diabetic control. J Clin Pathol 1989; 42: 502–5

    Article  CAS  PubMed  Google Scholar 

  56. AIDS Infonet. Older people and HIV. Factsheet no. 616. 2007 May 5. Body Health Resources Corporation [online]. Available from URL: http://www.thebody.com/content/art6036.html [Accessed 2007 Nov 1]

  57. Health Promotion Agency Communicable Disease Surveillance Centre (HIV & STI department) and the Scottish Centre for Infection & Environmental Health: unpublished quarterly surveillance tables no. 75, 07/02, August 2007 [online]. Available from URL: http://www.hpa.org.uk/infections/topics_AZ/hiv_and_sti/hiv/epidemiology/hars_tables.htm [Accessed 2007 Nov 1]

  58. Martinez Hernandez PL, Valencia Ortega ME, Pena Sanchez de Rivera JM, et al. HIV infection in old age: an epidemiological and clinical study in 42 patients in Madrid. Rev Clin Esp 1997; 197: 684–9

    CAS  PubMed  Google Scholar 

  59. Kassu A, Mekonnen A, Bekele A, et al. HIV and syphilis infection among elderly people in NW Ethiopia. Jpn J Infect Dis 2004; 57: 264–7

    PubMed  Google Scholar 

  60. Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection: a prospective study of 110 patients. Arch Intern Med 1991; 151: 1567–72

    Article  CAS  PubMed  Google Scholar 

  61. Fauci AS. HIV: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617–22

    Article  CAS  PubMed  Google Scholar 

  62. Smith PD, Ohura K, Masur H, et al. Monocyte function in AIDS. J Clin Invest 1984; 74: 2121–8

    Article  CAS  PubMed  Google Scholar 

  63. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–89

    Article  PubMed  Google Scholar 

  64. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer and neutropenia. BMJ 1997; 314: 1238–44

    Article  CAS  PubMed  Google Scholar 

  65. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: a prospective randomised double blind controlled study. J Infect Dis 1995; 171: 45–52

    Article  Google Scholar 

  66. Rotstein C, Bow EJ, Laverdiere M, et al. Randomised placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: benefits based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331–40

    Article  CAS  PubMed  Google Scholar 

  67. Shuto H, Nagata M, Terashi Y, et al. Esophageal candidiasis as a complication of inhaled steroid therapy. Jpn J Allerg 2003; 52: 1053–64

    Google Scholar 

  68. Kobayashi Y, Yasuba H, Kudou M, et al. Esophageal Candida as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to beclomethasone dipropionate. Int J Clin Pharm 2006; 44: 193–7

    CAS  Google Scholar 

  69. Stall R, Catania JA, Pollack L. Social epidemiology of AIDS and HIV infection among older Americans. In: Riley MW, Ory MC, Zablotsky D, editors. AIDS in an aging society. New York: Springer Publishing Co., 1993: 60–76

    Google Scholar 

  70. Catania JA, Turner H, Kegeies SM, et al. HIV transmission: risk of older heterosexuals and gays. In: Riley MW, Ory MC, Zablotsky D, editors. AIDS in an aging society. New York: Springer Publishing Co., 1993: 77–95

    Google Scholar 

  71. Anderson K, Gorgone R, Marlink R, et al. Transfusion acquired HIV infection among immunocompromised persons. Ann Intern Med 1986; 105: 519–27

    CAS  PubMed  Google Scholar 

  72. Peterman TR, Stoneburner J, Allen H, et al. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988; 259: 55–8

    Article  CAS  PubMed  Google Scholar 

  73. Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in HIV infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938–41

    CAS  PubMed  Google Scholar 

  74. Kaplon JE, Maur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002 Jun 14; 51(RR-8): 1–52

    Google Scholar 

  75. Kaplan JE, Hansen D, Dworkin MS, et al. Epidemiology of HIV associated opportunistic infections in the US in the era of HAART. Clin Infect Dis 2000; 30: S5–14

    Article  PubMed  Google Scholar 

  76. WHO/UNAID/UNICEF. Joint news release April 2007, London

  77. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339–46

    Article  CAS  PubMed  Google Scholar 

  78. Olmos MA, Araya V, Concetti H, et al. Oesophageal candidiasis: clinical and mycological analysis. Acta Gastroenterol Latinoam 2005; 35(4): 211–8

    PubMed  Google Scholar 

  79. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662–78

    Article  CAS  PubMed  Google Scholar 

  80. Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent) 2003 Apr; 16(2): 241–8

    Google Scholar 

  81. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003 Mar 1; 36(5): 630–7

    Article  CAS  PubMed  Google Scholar 

  82. Maschmeyer G, Glasmacher A. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 2005; 48: 227–34

    Article  CAS  PubMed  Google Scholar 

  83. Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78(4): 161–77

    Article  CAS  PubMed  Google Scholar 

  84. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501–17

    CAS  PubMed  Google Scholar 

  85. Vermes A, Guchelaar HA, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171–9

    Article  CAS  PubMed  Google Scholar 

  86. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992; 117: 655–60

    CAS  PubMed  Google Scholar 

  87. Barbaro B, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996; 111(5): 1169–77

    Article  CAS  PubMed  Google Scholar 

  88. Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227–32

    Article  CAS  PubMed  Google Scholar 

  89. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004 Sep 15; 39(6): 842–9

    Article  PubMed  Google Scholar 

  90. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005 Apr 1; 21(7): 899–907

    Article  PubMed  Google Scholar 

  91. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27: 377–83

    Article  CAS  PubMed  Google Scholar 

  92. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients: a double-blind, multicenter placebo-controlled study: the Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Chest 1996 Dec; 110(6): 1507–14

    Article  CAS  PubMed  Google Scholar 

  93. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39(1): 1–8

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Geriatrics and General Internal Medicine, Kings Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL, UK

    Namal Weerasuriya &  Jeremy Snape

Authors
  1. Namal Weerasuriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeremy Snape
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeremy Snape.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weerasuriya, N., Snape, J. Oesophageal Candidiasis in Elderly Patients. Drugs Aging 25, 119–130 (2008). https://doi.org/10.2165/00002512-200825020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200825020-00004

Keywords

Search

Navigation